BC Week In Review | May 27, 2013
Company News

J&J, Royal DSM deal

DSM said that on April 13, 2012, Percivia LLC terminated the PER.C6 biosimilars product development business as part of a restructuring of the company. Percivia, formerly Percivia PER.C6 Development Center, was established in 2006 to...
BC Week In Review | Apr 11, 2011
Company News

Percivia management update

Percivia LLC , Cambridge, Mass.   Business: Biomanufacturing   Hired: Amit Munshi as president and CEO, he is the co-founder and former CBO of Kythera Biopharmaceuticals Inc. as well as a co-founder and a director at...
BC Week In Review | Oct 11, 2010
Company News

Crucell, Royal DSM deal

Crucell and DSM said their 50/50 JV, Percivia PER.C6 Development Center is now an autonomous, biopharmaceutical company focused on PER.C6-based biobetter proteins and mAbs. Biobetters are biopharmaceuticals with similar targets and indications as existing biologics,...
BC Week In Review | Feb 12, 2007
Company News

Crucell, DSM Biologics N.V. deal

CRXL and DSM expanded a 2002 deal under which the companies jointly license CRXL's PER.C6 cell line to third parties to produce MAbs and therapeutic proteins (see BioCentury, Dec. 23, 2002). The deal will now...
Items per page:
1 - 4 of 4
BC Week In Review | May 27, 2013
Company News

J&J, Royal DSM deal

DSM said that on April 13, 2012, Percivia LLC terminated the PER.C6 biosimilars product development business as part of a restructuring of the company. Percivia, formerly Percivia PER.C6 Development Center, was established in 2006 to...
BC Week In Review | Apr 11, 2011
Company News

Percivia management update

Percivia LLC , Cambridge, Mass.   Business: Biomanufacturing   Hired: Amit Munshi as president and CEO, he is the co-founder and former CBO of Kythera Biopharmaceuticals Inc. as well as a co-founder and a director at...
BC Week In Review | Oct 11, 2010
Company News

Crucell, Royal DSM deal

Crucell and DSM said their 50/50 JV, Percivia PER.C6 Development Center is now an autonomous, biopharmaceutical company focused on PER.C6-based biobetter proteins and mAbs. Biobetters are biopharmaceuticals with similar targets and indications as existing biologics,...
BC Week In Review | Feb 12, 2007
Company News

Crucell, DSM Biologics N.V. deal

CRXL and DSM expanded a 2002 deal under which the companies jointly license CRXL's PER.C6 cell line to third parties to produce MAbs and therapeutic proteins (see BioCentury, Dec. 23, 2002). The deal will now...
Items per page:
1 - 4 of 4